CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats.

[1]  J. Nandini.,et al.  Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. , 2016, Journal of the science of food and agriculture.

[2]  P. Neuvonen,et al.  Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions , 2016, Pharmacological Reviews.

[3]  Hongjiang Zhang,et al.  Transmembrane transport of steviol glucuronide and its potential interaction with selected drugs and natural compounds. , 2015, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  T. Izumi,et al.  Liver-selective distribution in rats supports the importance of active uptake into the liver via organic anion transporting polypeptides (OATPs) in humans. , 2015, Drug metabolism and pharmacokinetics.

[5]  T. Hayakawa,et al.  Drug−drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes , 2015, Basic & clinical pharmacology & toxicology.

[6]  Feng Chen,et al.  Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data. , 2015, Current drug metabolism.

[7]  P. Neuvonen,et al.  Glucuronidation Converts Clopidogrel to a Strong Time‐Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions , 2014, Clinical pharmacology and therapeutics.

[8]  P. Neuvonen,et al.  In Vitro Assessment of Time-Dependent Inhibitory Effects on CYP2C8 and CYP3A Activity by Fourteen Protein Kinase Inhibitors , 2014, Drug Metabolism and Disposition.

[9]  P. Pan,et al.  Pathway-Dependent Inhibition of Paclitaxel Hydroxylation by Kinase Inhibitors and Assessment of Drug–Drug Interaction Potentials , 2014, Drug Metabolism and Disposition.

[10]  Hongjiang Zhang,et al.  Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[11]  A. Kalgutkar,et al.  Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development , 2013, Drug Metabolism and Disposition.

[12]  C. Bundgaard,et al.  The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Yuichi Sugiyama,et al.  Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes , 2013, Drug Metabolism and Disposition.

[14]  A. Galetin,et al.  A Comprehensive Assessment of Repaglinide Metabolic Pathways: Impact of Choice of In Vitro System and Relative Enzyme Contribution to In Vitro Clearance , 2012, Drug Metabolism and Disposition.

[15]  E. Thévenot,et al.  Can a cocktail designed for phenotyping pharmacokinetics and metabolism enzymes in human be used efficiently in rat? , 2012, Xenobiotica; the fate of foreign compounds in biological systems.

[16]  J. Mak,et al.  In vitro modulatory effects of flavonoids on human cytochrome P450 2C8 (CYP2C8) , 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

[17]  A. D. Rodrigues,et al.  Studies to Further Investigate the Inhibition of Human Liver Microsomal CYP2C8 by the Acyl-β-Glucuronide of Gemfibrozil , 2011, Drug Metabolism and Disposition.

[18]  P. Neuvonen,et al.  Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses , 2011, Drug Metabolism and Disposition.

[19]  Dominic P. Williams,et al.  Acyl glucuronides: the good, the bad and the ugly. , 2010, Biopharmaceutics & drug disposition.

[20]  L. Qian,et al.  Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver , 2010, Journal of Lipid Research.

[21]  M. Rieder,et al.  Human Liver Expression of CYP2C8: Gender, Age, and Genotype Effects , 2010, Drug Metabolism and Disposition.

[22]  Shu-Feng Zhou,et al.  Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. , 2009, Current drug metabolism.

[23]  C. Aquilante,et al.  Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. , 2009, Pharmacogenomics.

[24]  Alex Phipps,et al.  Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction , 2009, Drug Metabolism and Disposition.

[25]  H. Schatz.  Preclinical and clinical studies on safety and tolerability of repaglinide , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[26]  P. Neuvonen,et al.  The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. , 2008, British journal of clinical pharmacology.

[27]  A. Wheeler,et al.  Pharmacokinetics of rebaudioside A and stevioside after single oral doses in healthy men. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  Sang Chung,et al.  New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process , 2008, Journal of clinical pharmacology.

[29]  L J Lesko,et al.  Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.

[30]  R. de Kanter,et al.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction , 2006, Expert opinion on drug metabolism & toxicology.

[31]  J. Buyse,et al.  Identification of steviol glucuronide in human urine. , 2006, Journal of agricultural and food chemistry.

[32]  F. Guengerich,et al.  Cytochrome P450s and other enzymes in drug metabolism and toxicity , 2006, The AAPS Journal.

[33]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[34]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[35]  P. Neuvonen,et al.  Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. , 2005, Basic & clinical pharmacology & toxicology.

[36]  A. Rettie,et al.  Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance , 2005, Clinical pharmacology and therapeutics.

[37]  Richard King,et al.  Negative ion tandem mass spectrometry for the detection of glutathione conjugates. , 2005, Chemical research in toxicology.

[38]  Barry C. Jones,et al.  DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS , 2004, Drug Metabolism and Disposition.

[39]  Hannah M Jones,et al.  SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS , 2004, Drug Metabolism and Disposition.

[40]  P. Neuvonen,et al.  The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. , 2004, British journal of clinical pharmacology.

[41]  Xinxin Ding,et al.  Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. , 2003, Annual review of pharmacology and toxicology.

[42]  J. Ware,et al.  Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[43]  P. Neuvonen,et al.  Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide , 2003, Clinical pharmacology and therapeutics.

[44]  I. Bjørnsdottir,et al.  CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. , 2003, British journal of clinical pharmacology.

[45]  M. Bailey,et al.  Acyl glucuronide reactivity in perspective: biological consequences. , 2003, Chemico-biological interactions.

[46]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[47]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[48]  R. Obach,et al.  Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[49]  Y. Sugiyama,et al.  Drug interaction between simvastatin and itraconazole in male and female rats. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[50]  Yuichi Sugiyama,et al.  Quantitative Prediction of In Vivo Drug-Drug Interactions from In Vitro Data Based on Physiological Pharmacokinetics: Use of Maximum Unbound Concentration of Inhibitor at the Inlet to the Liver , 2000, Pharmaceutical Research.

[51]  M. S. Christensen,et al.  Single‐Dose Pharmacokinetics of Repaglinide in Subjects with Chronic Liver Disease , 2000, Journal of clinical pharmacology.

[52]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[53]  A. Parkinson,et al.  Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. , 1996, Archives of biochemistry and biophysics.

[54]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[55]  M. Dixon.  The graphical determination of Km and Ki , 1972 .

[56]  B. Jarvis,et al.  Repaglinide , 2012, Drugs.

[57]  A. Scheen.  Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide , 2007, Clinical pharmacokinetics.